Quantum Genesis AI Corp. Files Amended 10-Q/A: Key Updates on Intellectual Property, Financial Condition, and Going Concern Risks

Quantum Genesis AI Corp. (QGAI), a Nevada-based company engaged in the field of industrial organic chemicals and enzyme design technologies, has filed an Amendment No. 1 to its Quarterly Report on Form 10-Q for the period ended January 31, 2026. The amendment was filed to provide expanded details on the company’s intellectual property and formalize the assignment of certain patent rights, a potentially material update for shareholders and investors. Below, we break down the critical highlights and implications for shareholders.

Key Highlights from the Amended Filing

• No Revenue; Higher Net Losses: For the three and six months ended January 31, 2026, Quantum Genesis AI Corp. reported no revenues, consistent with the prior-year periods. However, the company recorded significantly higher net losses, mainly due to a substantial loss on settlement of debt:
  • Net loss for the quarter: \$4,329,657 (vs. \$29,806 for the prior year period)
  • Net loss for the six months: \$4,379,525 (vs. \$89,329 for the prior year period)
• Operating Expenses: Operating expenses decreased to \$1,382 for the three months and \$40,578 for the six months, attributed to lower professional fees. Despite the current decrease, the company expects operating expenses to rise in future years as its business model ramps up.
• Loss on Settlement of Debt: The spike in net loss is mainly due to a one-time, non-operating expense of \$4,328,275 (three months) and \$4,338,947 (six months) related to the settlement of debt. This is a significant event that directly impacts the company’s financial position and could influence share value.

Going Concern Warning

• The company’s auditors have raised substantial doubt about Quantum Genesis AI Corp.’s ability to continue as a going concern. As of January 31, 2026, the company had:
  • Total current assets: \$59
  • Total current liabilities: \$418,401
  • Working capital deficit: \$418,342
  • Accumulated deficit: \$10,016,092
• The company used \$43,810 in cash for operations during the six months and is entirely dependent on its ability to raise new capital, either through securities sales, private investment, or strategic partners. There are currently no firm agreements in place for such funding. The inability to secure funding could force the company to suspend operations, which may result in a total loss for shareholders.

Intellectual Property: Asset Formalization and Assignment

• Material Update: The amendment’s primary purpose was to clarify and formalize the company’s intellectual property rights related to enzyme design technologies.
  • The company’s IP includes proprietary enzyme design technologies and computational methodologies acquired via an Asset Purchase Agreement (APA) dated February 21, 2023.
  • Key Patent Application: U.S. Patent Application Publication No. US20250146029A1, titled “Modified Polypeptides for Enzymatic Synthesis of Ibuprofen,” filed November 2, 2023, is central to the company’s IP portfolio.
  • This patent application was originally filed in the name of the CEO, Naveen Krishnarao Kulkarni, but the company has now formalized the assignment of all rights, title, and interest in the underlying IP from the CEO to Quantum Genesis AI Corp. via an Assignment Agreement. The assignment is effective as of November 2, 2023, and confirms that the company holds full and exclusive rights to the IP.
• Potential Share Price Impact: The formalization of IP ownership removes a key legal risk and strengthens the company’s position to commercialize or license its technologies. Any positive developments in patent prosecution or commercial partnerships could be highly material.

Other Notable Disclosures

• Emerging Growth and Smaller Reporting Company: The company qualifies as both, which may allow for reduced reporting requirements and transition periods for new accounting pronouncements.
• No Securities Registered under Section 12(b): The company does not have securities listed on a national securities exchange.
• Share Structure: As of March 19, 2026, Quantum Genesis AI Corp. had 40,972,050 shares of common stock issued and outstanding.

Implications for Shareholders and Potential Price Sensitivity

• The assignment and formalization of IP rights is a critical milestone that de-risks the company’s asset base and may enhance shareholder value if the company can successfully commercialize or license its enzyme design technologies.
• The substantial loss and going concern warning are negative signals; the company’s extreme reliance on external funding, coupled with a significant working capital deficit, means that dilution or operational suspension risks are high. Any news of capital raising (or failure thereof) will likely have a major impact on share price.
• The successful prosecution of its key patent application or news of commercial partnerships could become significant catalysts for the stock. Conversely, inability to secure funding or IP disputes could materially harm shareholder value.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The information is based on the company’s public filings as of April 15, 2026, and may be subject to change without notice.

View Quantum Genesis AI Corp. Historical chart here